Edition:
India

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

50.81USD
11:42pm IST
Change (% chg)

$1.30 (+2.63%)
Prev Close
$49.51
Open
$49.84
Day's High
$51.56
Day's Low
$49.51
Volume
101,828
Avg. Vol
305,887
52-wk High
$67.10
52-wk Low
$17.20

Chart for

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $3,564.08
Shares Outstanding(Mil.): 64.17
Dividend: --
Yield (%): --

Financials

BRIEF-Portola Pharmaceuticals appoints John Lawrence as chief medical officer

* Portola Pharmaceuticals appoints industry veteran John H. Lawrence, M.D., as senior vice president of product development and chief medical officer Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Portola announces pricing of public offering of common stock at $55 per share

* Portola announces pricing of public offering of common stock

13 Sep 2017

BRIEF-Portola Pharma announces proposed offering of common stock

* Portola Pharmaceuticals announces proposed offering of common stock

12 Sep 2017

BRIEF-Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018

* Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA

15 Aug 2017

BRIEF-Portola Pharmaceuticals reports Q2 loss per share of $1.22

* Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

10 Aug 2017

BRIEF-Portola announces resubmission of BLA for Andexxa

* Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa)

04 Aug 2017

Portola shares soar after FDA approves clot preventing drug

WASHINGTON The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

24 Jun 2017

UPDATE 3-Portola shares soar after FDA approves clot preventing drug

WASHINGTON, June 23 The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

24 Jun 2017

U.S. FDA approves Portola blood-thinner to prevent blood clots

June 23 The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc. to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

23 Jun 2017

BRIEF-Portola Pharmaceuticals interim data from a phase 2A study evaluating Cerdulatinib

* Interim data from a phase 2A study evaluating Cerdulatinib in patients with relapsed/refractory B-cell malignancies

15 Jun 2017

Competitors

  Price Chg
Bayer AG (BAYGn.DE) €109.65 +1.00
Bayer AG (BAYE.F) -- --
Bristol-Myers Squibb Co (BMY.N) $61.63 +0.83
Bristol-Myers Squibb Co (BMYMP.PK) $1,033.00 -0.90

Earnings vs. Estimates